- Home
- PHUN vs JSPR Comparison
PHUN vs JSPR Comparison
Compare PHUN & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- JSPR
- Stock Information
- Founded
- PHUN 2009
- JSPR 2018
- Country
- PHUN United States
- JSPR United States
- Employees
- PHUN N/A
- JSPR N/A
- Industry
- PHUN EDP Services
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHUN Technology
- JSPR Health Care
- Exchange
- PHUN Nasdaq
- JSPR Nasdaq
- Market Cap
- PHUN 62.1M
- JSPR 85.8M
- IPO Year
- PHUN N/A
- JSPR N/A
- Fundamental
- Price
- PHUN $2.77
- JSPR $5.38
- Analyst Decision
- PHUN Strong Buy
- JSPR Strong Buy
- Analyst Count
- PHUN 3
- JSPR 11
- Target Price
- PHUN $13.00
- JSPR $62.50
- AVG Volume (30 Days)
- PHUN 390.0K
- JSPR 363.3K
- Earning Date
- PHUN 05-08-2025
- JSPR 02-27-2025
- Dividend Yield
- PHUN N/A
- JSPR N/A
- EPS Growth
- PHUN N/A
- JSPR N/A
- EPS
- PHUN N/A
- JSPR N/A
- Revenue
- PHUN $3,537,000.00
- JSPR N/A
- Revenue This Year
- PHUN N/A
- JSPR N/A
- Revenue Next Year
- PHUN $93.33
- JSPR N/A
- P/E Ratio
- PHUN N/A
- JSPR N/A
- Revenue Growth
- PHUN N/A
- JSPR N/A
- 52 Week Low
- PHUN $2.70
- JSPR $4.55
- 52 Week High
- PHUN $14.60
- JSPR $31.01
- Technical
- Relative Strength Index (RSI)
- PHUN 31.80
- JSPR 35.41
- Support Level
- PHUN $2.78
- JSPR $5.02
- Resistance Level
- PHUN $2.99
- JSPR $5.64
- Average True Range (ATR)
- PHUN 0.22
- JSPR 0.44
- MACD
- PHUN 0.01
- JSPR 0.19
- Stochastic Oscillator
- PHUN 8.00
- JSPR 26.45
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.